APA (7th ed.) Citation

Hehlmann, R., Müller, M. C., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., . . . Saußele, S. (2014). Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV. Journal of clinical oncology, 32(5), . https://doi.org/10.1200/JCO.2013.49.9020

Chicago Style (17th ed.) Citation

Hehlmann, Rüdiger, Martin Christian Müller, Benjamin Hanfstein, Alice Fabarius, Annette Schreiber, Ulrike Proetel, Jolanta Dengler, and Susanne Saußele. "Deep Molecular Response Is Reached by the Majority of Patients Treated with Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-dose Imatinib: Results from the Randomized CML-study IV." Journal of Clinical Oncology 32, no. 5 (2014). https://doi.org/10.1200/JCO.2013.49.9020.

MLA (9th ed.) Citation

Hehlmann, Rüdiger, et al. "Deep Molecular Response Is Reached by the Majority of Patients Treated with Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-dose Imatinib: Results from the Randomized CML-study IV." Journal of Clinical Oncology, vol. 32, no. 5, 2014, https://doi.org/10.1200/JCO.2013.49.9020.